Skip to main content Skip to main navigation menu Skip to site footer
  • Register
  • Login
  • Menu
  • Home
  • Current
  • Archives
  • Announcements
  • About
    • About the Journal
    • Submissions
    • Editorial Team
    • Privacy Statement
    • Contact
  • Register
  • Login

Journal of Education, Health and Sport

Novel immunotherapy in the management of advanced urothelial cancer - review of the literature
  • Home
  • /
  • Novel immunotherapy in the management of advanced urothelial cancer - review of the literature
  1. Home /
  2. Archives /
  3. Vol. 12 No. 8 (2022) /
  4. Review Articles

Novel immunotherapy in the management of advanced urothelial cancer - review of the literature

Authors

  • Paulina Chmiel Faculty of Medicine, Medical University of Lublin, Aleje Racławickie1, 20-059 Lublin https://orcid.org/0000-0002-2608-5319
  • Martyna Kłosińska Uniwersytet Medyczny w Lublinie https://orcid.org/0000-0001-7649-085X
  • Agnieszka Kaczyńska Uniwersytet Medyczny w Lublinie https://orcid.org/0000-0002-8943-9401

DOI:

https://doi.org/10.12775/JEHS.2022.12.08.036

Keywords

bladder cancer, urothelial carcinoma, immunotherapy, checkpoints inhibitors

Abstract

Bladder neoplasms, with the most common urothelial carcinoma, are responsible for approximately 200,000 deaths annually, which is 2.1% of the total cancer deaths in 2018. Recent decades have brought a steadily growing share of this cancer in the statistics. The 5-year survival rate is 77.1% for the United States and it varies depending on the stage of the diagnosed neoplasm, from 96% for cancer in situ to only 5% for the disseminated form with distant metastases. The treatment of urothelial cancer can be divided depending on the stage and advancement. Three main categories of bladder cancer can be distinguished: non-muscle invasive bladder cancer, treated by surgical approaches, and muscle-invasive bladder cancer, treated with chemotherapeutics, lastly advanced bladder cancer with distant metastases, treated with intensive chemotherapy in the MVAC scheme (methotrexate, vinblastine, doxorubicin, and cisplatin). Recently introduced checkpoint inhibitors have revolutionized the treatment of patients with metastatic urothelial carcinoma by increasing patient life expectancy, progression-free survival, and durability of clinical response. This review of the literature will discuss the use of immunotherapy in the treatment of advanced bladder cancer.

References

Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin (2021) 71:209–249. doi: 10.3322/caac.21660

Wojciechowska U, Didkowska J. Nowotwory Złośliwe w Polsce w 2018. Kraj Rejestr Nowotworów (2020)3–4, 31–63. http://onkologia.org.pl/raporty/dostęp z dnia 29/06/2021

Saginala K, Barsouk A, Aluru JS, Rawla P, Padala SA, Barsouk A. Epidemiology of Bladder Cancer. Med Sci (2020) 8:15. doi: 10.3390/medsci8010015

Antoni S, Ferlay J, Soerjomataram I, Znaor A, Jemal A, Bray F. Bladder Cancer Incidence and Mortality: A Global Overview and Recent Trends. Eur Urol (2017) 71:96–108. doi: 10.1016/j.eururo.2016.06.010

Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin (2019) 69:7–34. doi: 10.3322/caac.21551

Miyazaki J, Nishiyama H. Epidemiology of urothelial carcinoma. Int J Urol (2017) 24:730–734. doi: 10.1111/iju.13376

Zaghloul MS. Bladder cancer and schistosomiasis. J Egypt Natl Canc Inst (2012) 24:151–159. doi: 10.1016/j.jnci.2012.08.002

Wong MCS, Fung FDH, Leung C, Cheung WWL, Goggins WB, Ng CF. The global epidemiology of bladder cancer: a joinpoint regression analysis of its incidence and mortality trends and projection. Sci Rep (2018) 8:1129. doi: 10.1038/s41598-018-19199-z

Ferwana M, Firwana B, Hasan R, Al-Mallah MH, Kim S, Montori VM, Murad MH. Pioglitazone and risk of bladder cancer: a meta-analysis of controlled studies. Diabet Med (2013) 30:1026–1032. doi: 10.1111/dme.12144

Zhu Z, Wang X, Shen Z, Lu Y, Zhong S, Xu C. Risk of bladder cancer in patients with diabetes mellitus: an updated meta-analysis of 36 observational studies. BMC Cancer (2013) 13:310. doi: 10.1186/1471-2407-13-310

Mostafa MH, Sheweita SA, O’connor PJ. Relationship between Schistosomiasis and Bladder Cancer. (1999). 97–111 p. https://journals.asm.org/journal/cmr

Babjuk M, Burger M, Compérat EM, Gontero P, Mostafid AH, Palou J, van Rhijn BWG, Rouprêt M, Shariat SF, Sylvester R, et al. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update. Eur Urol (2019) 76:639–657. doi: 10.1016/J.EURURO.2019.08.016

Humphrey PA, Moch H, Cubilla AL, Ulbright TM, Reuter VE. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part B: Prostate and Bladder Tumours. Eur Urol (2016) 70:106–119. doi: 10.1016/j.eururo.2016.02.028

Minoli M, Kiener M, Thalmann GN, Kruithof-de Julio M, Seiler R. Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. Int J Mol Sci (2020) 21:5670. doi: 10.3390/ijms21165670

Warrick JI, Knowles MA, Yves A, van der Kwast T, Grignon DJ, Kristiansen G, Egevad L, Hartmann A, Cheng L. Report From the International Society of Urological Pathology (ISUP) Consultation Conference On Molecular Pathology Of Urogenital Cancers. II. Molecular Pathology of Bladder Cancer. Am J Surg Pathol (2020) 44:e30–e46. doi: 10.1097/PAS.0000000000001453

Lokeshwar SD, Lopez M, Sarcan S, Aguilar K, Morera DS, Shaheen DM, Lokeshwar BL, Lokeshwar VB. Molecular Oncology of Bladder Cancer from Inception to Modern Perspective. Cancers (Basel) (2022) 14:2578. doi: 10.3390/cancers14112578

Moschini M, D’Andrea D, Korn S, Irmak Y, Soria F, Compérat E, Shariat SF. Characteristics and clinical significance of histological variants of bladder cancer. Nat Rev Urol (2017) 14:651–668. doi: 10.1038/NRUROL.2017.125

Lopez-Beltran A, Henriques V, Montironi R, Cimadamore A, Raspollini MR, Cheng L. Variants and new entities of bladder cancer. Histopathology (2019) 74:77–96. doi: 10.1111/HIS.13752

Rieken M, Shariat SF, Kluth L, Crivelli JJ, Abufaraj M, Foerster B, Mari A, Ilijazi D, Karakiewicz PI, Babjuk M, et al. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer. Urol Oncol Semin Orig Investig (2018) 36:8.e17-8.e24. doi: 10.1016/j.urolonc.2017.08.027

Sylvester RJ, Oosterlinck W, Holmang S, Sydes MR, Birtle A, Gudjonsson S, De Nunzio C, Okamura K, Kaasinen E, Solsona E, et al. Systematic Review and Individual Patient Data Meta-analysis of Randomized Trials Comparing a Single Immediate Instillation of Chemotherapy After Transurethral Resection with Transurethral Resection Alone in Patients with Stage pTa–pT1 Urothelial Carcinoma. Eur Urol (2016) 69:231–244. doi: 10.1016/j.eururo.2015.05.050

Dinney CPN, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, et al. Focus on bladder cancer. Cancer Cell (2004) 6:111–116. doi: 10.1016/j.ccr.2004.08.002

Powles T, Park SH, Voog E, Caserta C, Valderrama BP, Gurney H, Kalofonos H, Radulović S, Demey W, Ullén A, et al. Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma. N Engl J Med (2020) 383:1218–1230. doi: 10.1056/NEJMoa2002788

Witjes JA, Bruins HM, Cathomas R, Compérat EM, Cowan NC, Gakis G, Hernández V, Linares Espinós E, Lorch A, Neuzillet Y, et al. European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines. Eur Urol (2021) 79:82–104. doi: 10.1016/j.eururo.2020.03.055

Meeks JJ, Bellmunt J, Bochner BH, Clarke NW, Daneshmand S, Galsky MD, Hahn NM, Lerner SP, Mason M, Powles T, et al. A Systematic Review of Neoadjuvant and Adjuvant Chemotherapy for Muscle-invasive Bladder Cancer. Eur Urol (2012) 62:523–533. doi: 10.1016/j.eururo.2012.05.048

Bamias A, Tzannis K, Harshman LC, Crabb SJ, Wong Y-N, Kumar Pal S, De Giorgi U, Ladoire S, Agarwal N, Yu EY, et al. Impact of contemporary patterns of chemotherapy utilization on survival in patients with advanced cancer of the urinary tract: a Retrospective International Study of Invasive/Advanced Cancer of the Urothelium (RISC). Ann Oncol (2018) 29:361–369. doi: 10.1093/annonc/mdx692

Mertens LS, Meijer RP, Kerst JM, Bergman AM, van Tinteren H, van Rhijn BWG, Horenblas S. Carboplatin Based Induction Chemotherapy for Nonorgan Confined Bladder Cancer—A Reasonable Alternative for Cisplatin Unfit Patients? J Urol (2012) 188:1108–1114. doi: 10.1016/j.juro.2012.06.018

Facchini G, Cavaliere C, Romis L, Mordente S. Advanced / metastatic bladder cancer : current status and future directions. (2020)11536–11552.

Patel VG, Oh WK, Galsky MD. Treatment of muscle‐invasive and advanced bladder cancer in 2020. CA Cancer J Clin (2020) 70:404–423. doi: 10.3322/caac.21631

Rhea LP, Mendez-Marti S, Kim D, Aragon-Ching JB. Role of immunotherapy in bladder cancer. Cancer Treat Res Commun (2021) 26:100296. doi: 10.1016/j.ctarc.2020.100296

Sharma P, Retz M, Siefker-Radtke A, Baron A, Necchi A, Bedke J, Plimack ER, Vaena D, Grimm M-O, Bracarda S, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol (2017) 18:312–322. doi: 10.1016/S1470-2045(17)30065-7

Wood LS, Conway D, Lapuente M, Salvador G, Fernandez Gomez S, Carroll Bullock A, Devgan G, Burns KD. Avelumab First-Line Maintenance Treatment in Advanced Bladder Cancer: Practical Implementation Steps for Infusion Nurses. J Infus Nurs (2022) 45:142–153. doi: 10.1097/NAN.0000000000000465

Galsky MD, Arija JÁA, Bamias A, Davis ID, De Santis M, Kikuchi E, Garcia-del-Muro X, De Giorgi U, Mencinger M, Izumi K, et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet (2020) 395:1547–1557. doi: 10.1016/S0140-6736(20)30230-0

Suzman DL, Agrawal S, Ning Y, Maher VE, Fernandes LL, Karuri S, Tang S, Sridhara R, Schroeder J, Goldberg KB, et al. FDA Approval Summary: Atezolizumab or Pembrolizumab for the Treatment of Patients with Advanced Urothelial Carcinoma Ineligible for Cisplatin-Containing Chemotherapy. Oncologist (2019) 24:563–569. doi: 10.1634/theoncologist.2018-0084

Necchi A, Joseph RW, Loriot Y, Hoffman-Censits J, Perez-Gracia JL, Petrylak DP, Derleth CL, Tayama D, Zhu Q, Ding B, et al. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study. Ann Oncol (2017) 28:3044–3050. doi: 10.1093/annonc/mdx518

Galsky MD, Saci A, Szabo PM, Han GC, Grossfeld G, Collette S, Siefker-Radtke A, Necchi A, Sharma P. Nivolumab in Patients with Advanced Platinum-resistant Urothelial Carcinoma: Efficacy, Safety, and Biomarker Analyses with Extended Follow-up from CheckMate 275. Clin Cancer Res (2020) 26:5120–5128. doi: 10.1158/1078-0432.CCR-19-4162

Kwok G, Yau TCC, Chiu JW, Tse E, Kwong Y-L. Pembrolizumab (Keytruda). Hum Vaccin Immunother (2016) 12:2777–2789. doi: 10.1080/21645515.2016.1199310

Bellmunt J, de Wit R, Vaughn DJ, Fradet Y, Lee J-L, Fong L, Vogelzang NJ, Climent MA, Petrylak DP, Choueiri TK, et al. Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. N Engl J Med (2017) 376:1015–1026. doi: 10.1056/NEJMoa1613683

Powles T, van der Heijden MS, Castellano D, Galsky MD, Loriot Y, Petrylak DP, Ogawa O, Park SH, Lee J-L, De Giorgi U, et al. Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol (2020) 21:1574–1588. doi: 10.1016/S1470-2045(20)30541-6

Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors. Clin Cancer Res (2019) 25:3753–3758. doi: 10.1158/1078-0432.CCR-18-4070

Downloads

  • PDF

Published

2022-08-09

How to Cite

1.
CHMIEL, Paulina, KŁOSIŃSKA, Martyna & KACZYŃSKA, Agnieszka. Novel immunotherapy in the management of advanced urothelial cancer - review of the literature. Journal of Education, Health and Sport [online]. 9 August 2022, T. 12, nr 8, s. 348–357. [accessed 27.3.2023]. DOI 10.12775/JEHS.2022.12.08.036.
  • PN-ISO 690 (Polish)
  • ACM
  • ACS
  • APA
  • ABNT
  • Chicago
  • Harvard
  • IEEE
  • MLA
  • Turabian
  • Vancouver
Download Citation
  • Endnote/Zotero/Mendeley (RIS)
  • BibTeX

Issue

Vol. 12 No. 8 (2022)

Section

Review Articles

License

Copyright (c) 2022 Paulina Chmiel, Martyna Kłosińska, Agnieszka Kaczyńska

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

The periodical offers access to content in the Open Access system under the Creative Commons Attribution-NonCommercial-ShareAlike 4.0

Stats

Number of views and downloads: 114
Number of citations: 0

Search

Search

Browse

  • Browse Author Index
  • Issue archive

User

User

Current Issue

  • Atom logo
  • RSS2 logo
  • RSS1 logo

Information

  • For Readers
  • For Authors
  • For Librarians

Newsletter

Subscribe Unsubscribe

Tags

Search using one of provided tags:

bladder cancer, urothelial carcinoma, immunotherapy, checkpoints inhibitors
Up

Akademicka Platforma Czasopism

Najlepsze czasopisma naukowe i akademickie w jednym miejscu

apcz.umk.pl

Partners

  • Akademia Ignatianum w Krakowie
  • Akademickie Towarzystwo Andragogiczne
  • Fundacja Copernicus na rzecz Rozwoju Badań Naukowych
  • Instytut Historii im. Tadeusza Manteuffla Polskiej Akademii Nauk
  • Instytut Kultur Śródziemnomorskich i Orientalnych PAN
  • Karmelitański Instytut Duchowości w Krakowie
  • Państwowa Akademia Nauk Stosowanych w Krośnie
  • Państwowa Akademia Nauk Stosowanych we Włocławku
  • Państwowa Wyższa Szkoła Zawodowa im. Stanisława Pigonia w Krośnie
  • Polskie Towarzystwo Ekonomiczne
  • Polskie Towarzystwo Ludoznawcze
  • Towarzystwo Miłośników Torunia
  • Towarzystwo Naukowe w Toruniu
  • Uniwersytet im. Adama Mickiewicza w Poznaniu
  • Uniwersytet Mikołaja Kopernika
  • Uniwersytet w Białymstoku
  • Uniwersytet Warszawski
  • Wojewódzka Biblioteka Publiczna - Książnica Kopernikańska
  • Wyższe Seminarium Duchowne w Pelplinie / Wydawnictwo Diecezjalne „Bernardinum" w Pelplinie

© 2021- Nicolaus Copernicus University Accessibility statement Shop